chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Loss of interest in routine activities; little loss of memory and forget things.; This spontaneous case was reported by a consumer and describes the occurrence of DECREASED INTEREST (Loss of interest in routine activities) and AMNESIA (little loss of memory and forget things.) in an 18-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 022C21A and 039B?1A) for COVID-19 vaccination.     Concurrent medical conditions included Mental retardation.   On 17-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 15-May-2021, the patient experienced DECREASED INTEREST (Loss of interest in routine activities) and AMNESIA (little loss of memory and forget things.). At the time of the report, DECREASED INTEREST (Loss of interest in routine activities) and AMNESIA (little loss of memory and forget things.) outcome was unknown.            Action taken with mRNA-1273 in response to the event was not applicable.  No concomitant medications were reported. Treatment information was unknown.
He developed mild Henoch Schonlein purpura 4 days after the vaccine. He is improving.
received the second dose / after the maximum recommended time of 6 months / first dose was administered / during Nov 23rd 2019; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 78-year-old female patient who received Herpes zoster (Shingrix) (batch number 7f94c, expiry date 11th November 2022) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on 23rd November 2019).   On 2nd July 2021, the patient received the 2nd dose of Shingrix. On 2nd July 2021, unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown.  Additional details were provided as follows: The patient received the 2nd dose of Shingrix after the maximum recommended time of 6 months, which led to lengthening of vaccination schedule. The reporter consented to follow up. The case is linked with the case- US2021143504, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021143504:Same reporter
Developed extreme peripheral neuropathy 5 days post vaccination. It was so severe that I had to take a lot of steroids and am still on loads of gabapentin for the nerve pain. For this reason I chose not to receive vaccination #2 even though I am a teacher and at risk as I was afraid I would become disabled and unable to work.
Information has been received from a physician concerning a 4 month old female who in 2007 was vaccinated PO with her second 2.0 ml dose of ROTATEQ. Concomitant vaccinations administered on that same day included "other required vaccinations." In 28-AUG-2007 the patient experienced vomiting, diarrhea and fever. The patient went to the ER on 30-AUG-2007, and two more office visits on 05-SEP-2007 and 07-SEp2007 her condition had not improved as of this time and was diagnosed as a viral infection. Therapy with ROTATEQ was discontinued for the third dose. There was no product quality complaint. Additional informtion has been requested.
Minor headache late evening on vaccination day the 24th around 2:00 pm. Next morning minor headache generally not feeling well, around noon headache became intense and pressure in my chest, so not comfortable lying down, sat up and walked around much of the night. Finally took ibuprofen which didn't help. Next day I was a bit tired but done with the headache and feeling of illness. Worst lasted about 12-15 hours.
1/3/2022 Moderate nosebleed for 15 minutes 1/6/2022 Severe nosebleed for 90 minutes (nose running like faucet, blood coming out of right eye tear duct, coughing up blood and blood clots, pressure on ears/in head when holding nostrils closed tightly) 1/9/2022 Severe nosebleed for 60 minutes (nose running slightly slower than 1/6/2022 incident, blood coming out of right eye tear duct, minimal coughing of blood)  Notes: Ice was applied during incidents, origin vessel appears to be in right nostril, use of ginger and tumeric stopped after 1/6/2022 incident, use of saline spray and vaseline was started after 1/6/2022 incident, last platelet count was taken in 2018 and was 284 (within normal range), outside air temperature in the local area dropped significantly between 1/1/2022 and 1/3/2022 and I have experienced nosebleeds for temperature changes in the past but the amount of blood and duration of the nosebleed are unprecedented.  I requested a doctor's appointment with the primary care physician listed in this report.
Approximately 5 hours after immunization patient's mother noted a slight red rash across chest. By the next AM body and head were covered in hive like rash, no respiratory difficulty. Rash lasted 3 days. Treated with Benadryl. This report was submitted in July and the Health Department is now sending it via the web.
pt recvd vax 7NOV04 & sx began 11NOV94, rash, wheals all over body including palms of hands & soles of feet; itchy; DPH given;
Numbness and pain started in my left thumb on 10/07. Numbness was constant and the shooting pain would come and go based on my activity level. The pain and numbness only bothered me during the daytime, never at night. By 10/10 the numbness had spread to include my whole left hand and wrist. My left hand also was very weak. The pain increased in intensity and the sharp pain was constant during waking hours on 10/10. This continued till 10/13 when the numbness started to spread up my arm to my shoudler and the shooting pains now included my elbow to my wrist. Over the next several weeks I self treated with Ibuprofen 800mg 4 times daily. The numbness, weakness and pain did subside over time. At this point I still have weakness in the left hand and still have to modify my behaviors to prevent the shooting pains.
Client stated tasting the vaccine in her mouth.  Then she reported experienced dyspnea onset similar as with bronchospasm with the inability to take a complete breath.  Client responded to 2 puffs of albuterol that were self administered.  The dyspnea resolved and the client was able to speak in complete sentences. Client experienced mild diaphoresis along with hypertension.  Client reported  prior to the onset of the dyspnea experience lightheadness.  The blood pressure initial reading was 200/119 and check every 5- 10 minutes following.  The blood pressure 15 minutes later was 164/101.  Additional 15 minutes later was 155/93.  HR during the event remained between 70-85.  The client denied pain during the event and following.  Client deferred transport to hospital.  The client advised to go to the ED for further eval of HTN but refused.
This spontaneous report was received from a physician via company representative regarding a patient of unknown age and gender. The patient's medical history, drug reactions or allergies were not provided. On an unknown date, the patient was vaccinated with a subcutaneous dose of ZOSTAVAX, (lot number and expiration date were not provided). Concomitant medications were not provided. On an unknown date, the patient experienced some form of shingles. At the time of the report, the patient's outcome was unknown. Causality was not provided. Additional information has been requested.
Headache, Fever,  Fatigue, hhills, injection site pain and swelling, tenderness and swelling of the local lymph nodes on the injection side, joint pain  Narrative:
Moderna COVID-19 Vaccine EUA  I believe the shot triggered a Lupus flare-up (beginning the evening of 3/30--date of the injection, and on-going). I developed bruising on my thighs, developed petechiae on my legs (common to my flare-ups), and was spotting (bleeding).  One week later, I am still very achy and lethargic. Also put me in a very depressed state. I have "mild Lupus" and typically only have a mild flare-up 3 or 4 times a year (and not lasting this long), so I am confident the injection triggered it. The bruising and spotting are new to me and not Lupus related, so those are of special concern.
worsening renal failure/kidney function continued to decline; gross hematuria; follicular conjunctivitis; a low CD3/CD4 count (CD4 91, CD347, CD8 258); a low CD3/CD4 count (CD4 91, CD347, CD8 258); The patient's unilateral tinnitus progressed to bilateral sensorineural deafness over 2 days; The patient's unilateral tinnitus progressed to bilateral sensorineural deafness over 2 days; pustular rash on his chin forehead, chest and back; nauseous; diffuse myalgia; vomited; suprapubic pain; This is a spontaneous report from a contactable other healthcare professional.   A 20-year-old male patient first dose of received bnt162b2 (BNT162B2), intramuscular, administered in left arm on 19Apr2021, at the age of 20-years old, (Lot Number: EW0151) as SINGLE DOSE for covid-19 immunisation.  The patient's medical history and concomitant medications were not reported. Prior to vaccination, the patient has not been diagnosed with COVID-19. It was reported that the patient was in his usual state of good health until 19Apr2021, when he received his first dose of the Pfizer COVID-19 vaccine. Two hours after the injection he became nauseous and vomited multiple times. Overnight he experienced diffuse myalgia and suprapubic pain. On 20Apr2021, he woke up the next day to a pustular rash on his chin, forehead, chest and back. The patient describes similar previous rashes that have resolved spontaneously. On21Apr2021, he began to experience gross hematuria and presented to the Emergency department. On the medicine floor he was initially found to have worsening renal failure, follicular conjunctivitis by skin biopsy, a low CD3/CD4 count (CD4 91, CD3 47, CD8 258) with normal complement, and bilateral tinnitus. The patient's unilateral tinnitus progressed to bilateral sensorineural deafness over 2 days. His kidney function continued to decline and hemodialysis was begun on 27Apr2021. His kidney function continued to decline on hemodialysis, becoming so he was transferred to the MICU for CRRT. The patient was hospitalized for 12 days due to the events, the events were also  assessed as life-threathening. The patient been tested for COVID-19 post vaccination with unknown result. The outcome of the events was unknown. Therapeutic measures were taken as a result of the events.  Information on Lot/Batch number was available. Additional information has been requested.
None stated. 9/9/09 Rheumatology consultant records received DOS 1/5/05 to 6/17/09. Assessment: Rheumatoid arthritis, uncontrolled anxiety. Patient presented with pain in (L) shoulder, (L) knee, hands and feet. Unable to lift (L) arm above head. Swelling in hands, nodules. Multiple joint swelling. Fatigue, weight loss, inability to function. Wrist pain. 'Hole in back of mouth'. Nausea, vomiting, dizzy, and sick. Left-sided chest pain. Lightheaded. Synovitis multiple joints. H. Pylori and diverticulosis. Vision and dental concerns.
On the afternoon of immunization, patient experienced pain at the site of pneumococcal vaccine which progressed to swelling and reddness with heat.  Swelling, reddness, and heat extends from axillary to wrist of left inner arm. Client notified MD day of onset and was instructed to take benadryl.  Client called today and instructed to come in for assessment.  Inner aspect of left arm with reddness from elbow to wrist, noted hot to touch and swelling. Client is post polio patient with residuals in this arm. Appointment made with MD to be seen today.  Per MD office will call client with appoint time.  Client instructed to call this nurse after visit with MD.  Will follow up with client on Monday.
Serious discomfort from elbow to shoulder on the 4th and 7th day after 2nd dose was given
Fatigue; Vaccination site pain; Headache; Injection site bruising; Injection site bleeding; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Fatigue), VACCINATION SITE PAIN (Vaccination site pain), HEADACHE (Headache), INJECTION SITE BRUISING (Injection site bruising) and INJECTION SITE HAEMORRHAGE (Injection site bleeding) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Panuveitis.    No Medical History information was reported.   In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In February 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate free. On an unknown date, the patient experienced FATIGUE (Fatigue), VACCINATION SITE PAIN (Vaccination site pain), HEADACHE (Headache), INJECTION SITE BRUISING (Injection site bruising) and INJECTION SITE HAEMORRHAGE (Injection site bleeding). At the time of the report, FATIGUE (Fatigue), VACCINATION SITE PAIN (Vaccination site pain) and HEADACHE (Headache) outcome was unknown and INJECTION SITE BRUISING (Injection site bruising) and INJECTION SITE HAEMORRHAGE (Injection site bleeding) had resolved.            No concomitant medications were reported. No treatment medications were reported. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. Primary reporter contact for lot number information was not available. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Patient experienced syncope 5 minuteas after administration. He was only briefly (seconds) affected and was subsequently examined by EMT with normal BP and pulse. No treatment was administered.
pt recvd Engerix-vax initial dose 17FEB93; on 18FEB93 devel hives treated w/DPH; on 19FEB93 devel erythema multiforme treated w/steroids recovery completed on follow-up 22FEB93; pt had hx of recurrent hives;
Has not received the second dose; Tenderness in both underarms; This spontaneous case was reported by a consumer and describes the occurrence of TENDERNESS (Tenderness in both underarms) and PRODUCT DOSE OMISSION ISSUE (Has not received the second dose) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Jun-2021, the patient experienced TENDERNESS (Tenderness in both underarms). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Has not received the second dose). The patient was treated with PARACETAMOL (TYLENOL) for Tenderness, at an unspecified dose and frequency. On 05-Jun-2021, TENDERNESS (Tenderness in both underarms) had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (Has not received the second dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The patient stated that she had not received the second dose of the Moderna COVID-19 vaccine.  No concomitant product use was provided by the reporter.  The patient received the first dose of the Moderna COVID-19 vaccine on 03June2021 and the dose was given in the patients left arms. The next day 04June2021, after the first dose the patient reported experiencing tenderness in both underarms. The patient explained the tenderness under the arms went away within 24 hours. The patient took Tylenol to help with the symptom. The patient does not take any daily medications. The patient stated they lost their vaccine card and they are unable to provide the lot number at this time. The patient has not received the second dose of the Moderna COVID-19 vaccine.
Patient was indicated to get full 3rd dose of Moderna vaccine, due to immunocompromised status. However, patient received booster dose of Moderna vaccine (from pharmacy) on 12/4/21.
Dizziness, feeling like I was going to faint if I moved my head side to side, fatigue, 100F fever, nausea, aches in hamstring muscles
pt began to have headache, chills, light headedness,  and sweating approx 12 minutes after administration of vaccine.  complained of throat feeling slightly constricted with feeling of gag reflex approximately 20 minutes after administration of vaccine.  pt  did not show signs or feel like lips or tongue were swelling but 50 mg liquid benedryl was given orally as a precaution. pt remained stable in described condition until was taken home by parent 50 minutes after initial vaccination time. pt contacted 2 hours later and reported no change in condition (neither better or worse)
This spontaneous report as received from a healthcare worker refers to a 4 month old patient of unknown gender. The patient's relevant medical history, current conditions and concomitant medications were not reported. On 05-NOV-2015 the patient was vaccinated with improperly stored ROTATEQ (dosing details were not reported) lot # L008053, with an expiry date of 30-NOV-2016, orally (incorrect product storage). The vaccine was administered at public health clinic or hospital with public funds. No adverse effects were reported. There was no product quality complaint involved. This is one of the several reports received from the same reporter. Additional information has been requested.
OFF LABEL USE; ADMINISTRATION OF EXPIRED VACCINE; VACCINE WAS ADMINISTERED 16 YEAR OLD PATIENT; This spontaneous report received from a parent concerned a 16 year old female. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 043A21A, and expiry: 19-SEP-2021) dose was not reported, administered on 24-NOV-2021 for prophylactic vaccination. No concomitant medications were reported.  On 24-NOV-2021, the patient experienced off label use. On 24-NOV-2021, the patient experienced administration of expired vaccine. On 24-NOV-2021, the patient experienced vaccine was administered 16 year old subject. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the administration of expired vaccine, vaccine was administered 16 year old patient and off label use was not reported. This report was non-serious.
Patient had a 4in by 4in red 2 inches under the injection site of the vaccine.
After first shot on 26 May 2021, light headed and ringing in ears, particularly in the right ear. Lightheadedness went away after 30 minutes but ringing remained. Faded slightly after a week but intensified immediately after the second shot on 16 June 2021. Had no other reactions after the second shot. Today, 29 July 2021, it is the strongest ringing I have experienced since taking the first shot. Adversely affecting my hearing and ability to focus. My primary care doctor set up a hearing test but says there is no treatment for this.
Jaw pain when she goes to eat; Lower calf cramping for a couple of days; Sore arm with her covid vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN JAW (Jaw pain when she goes to eat), MUSCLE SPASMS (Lower calf cramping for a couple of days) and PAIN IN EXTREMITY (Sore arm with her covid vaccine) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 2101734) for COVID-19 vaccination.    Co-suspect product included non-company product TREPROSTINIL SODIUM for Primary pulmonary hypertension.    Concurrent medical conditions included Pulmonary arterial hypertension. Concomitant products included RIOCIGUAT (ADEMPAS) and MACITENTAN (OPSUMIT) for an unknown indication.   On 13-Mar-2018, the patient started TREPROSTINIL SODIUM (unknown route) 5 mg/kg. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intravenous) 1 dosage form. On an unknown date, the patient experienced PAIN IN JAW (Jaw pain when she goes to eat), MUSCLE SPASMS (Lower calf cramping for a couple of days) and PAIN IN EXTREMITY (Sore arm with her covid vaccine). At the time of the report, PAIN IN JAW (Jaw pain when she goes to eat), MUSCLE SPASMS (Lower calf cramping for a couple of days) and PAIN IN EXTREMITY (Sore arm with her covid vaccine) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intravenous) was unknown.       Treatment information was not provided.   Reporter did not allow further contact
Super tired/exhausted; This is a spontaneous report from a contactable consumer (patient). This 90-year-old female patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL1283 and expiry date unknown), via an unspecified route of administration on 07Jan2021 at a single dose for COVID-19 immunization. Medical history included blood cholesterol abnormal and thyroid disorder. Concomitant medications included levothyroxine for thyroid, atorvastatin for cholesterol, and unspecified vitamins. When she got the first dose of the vaccine, she felt fine when she got it in the morning and then she felt super tired later in the evening. She went to bed about an hour early as she was just exhausted. She stated that at her age, she was always tired in the evening but she was just exhausted that evening. She got "no temperature". The patient felt fine/normal the next day. She felt as good as she usually did. She did not receive treatment for the event. Due date for the second dose was reported as 28Jan2021. Outcome of the event was recovered on 07Jan2021.
Syncope, hit head (5-10 min. after injections) Dizzy x 30 min after syncope
Local symptoms- Paine-discomfort. General Symptoms- Headache, joint pains, muscle pains, fatigue, nausea.  Narrative:
Sore arm immediately after injection, pain did not reduce until after 30 hours.  Severely sensitive/sore lymph node (armpit on injection arm) started at around 30 hours after injection.  Also, sweats and chills started at around 30 hours after injection.  Minor soreness in arm, severely sensitive/sore lymph node, sweats and chills all still present at 48 hours after injection.
Severe fatigue, malaise, low grade fever, loss of appetite, body aches, nausea
At one and a half hours after receiving her vaccine, developed tongue and throat swelling, went immediately to the ER. She was treated in the ER and was discharged to home with EPI pen. She still has the following symptoms headache, dizziness, lightheaded, fever 99.2. Difficulty concentration and talking. She is following up with her primary care physician on 12/21/2020
BODY ACHE; CHILLS; FEVER; HEADACHE; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's height, and weight were not reported.  The patient's past medical history included covid-19 infection. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be  requested for this case. No concomitant medications were reported.  On an unspecified date, the subject experienced body ache, chills, fever, and headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from body ache, chills, fever, and headache. This report was non-serious.
PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE ACUTE DVT OF RIGHT LEG, UNSPECIFIED VEIN ACUTE PULMONARY EMBOLISM